Phosphate binders

Results: 41



#Item
31April 3, 2013 Press Release Mitsubishi Tanabe Pharma Corporation Launch of BindRen® for Treatment of Hyperphosphatemia in Germany and Austria Osaka, Japan, April 3, 2013—Mitsubishi Tanabe Pharma Corporation (President

April 3, 2013 Press Release Mitsubishi Tanabe Pharma Corporation Launch of BindRen® for Treatment of Hyperphosphatemia in Germany and Austria Osaka, Japan, April 3, 2013—Mitsubishi Tanabe Pharma Corporation (President

Add to Reading List

Source URL: www.mt-pharma.co.jp

Language: English - Date: 2013-04-02 21:11:30
32Microsoft Word - Lanthanum_Consult_final.doc

Microsoft Word - Lanthanum_Consult_final.doc

Add to Reading List

Source URL: www.fda.gov

Language: English
33Microsoft Word - Calcium_Acetate_caps_21160_RC8-09.doc

Microsoft Word - Calcium_Acetate_caps_21160_RC8-09.doc

Add to Reading List

Source URL: www.fda.gov

Language: English
34PPPA Requirements; Proposed Exemption of Powder Formulations of Colesevelam Hydrochloride and Sevelamer Carbonate, Proposed Rule, 16 CFR Part 1700, CPSC Docket No. CPSC[removed], COMMENT REQUEST, (Petitions PP 10-1 and

PPPA Requirements; Proposed Exemption of Powder Formulations of Colesevelam Hydrochloride and Sevelamer Carbonate, Proposed Rule, 16 CFR Part 1700, CPSC Docket No. CPSC[removed], COMMENT REQUEST, (Petitions PP 10-1 and

Add to Reading List

Source URL: www.cpsc.gov

Language: English - Date: 2012-11-30 15:35:59
35SPECIAL AUTHORIZATION REQUEST FORM The Newfoundland and Labrador Prescription Drug Program (NLPDP) Request for Coverage of Sevelamer (Renagel)- Initiation and Renewal Pharmaceutical Services Department of Health and Comm

SPECIAL AUTHORIZATION REQUEST FORM The Newfoundland and Labrador Prescription Drug Program (NLPDP) Request for Coverage of Sevelamer (Renagel)- Initiation and Renewal Pharmaceutical Services Department of Health and Comm

Add to Reading List

Source URL: www.health.gov.nl.ca

Language: English - Date: 2012-12-18 09:02:01
36--------------------WARNINGS AND PRECAUTIONS--------------------HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FOSRENOL safely and effectively. See full prescribin

--------------------WARNINGS AND PRECAUTIONS--------------------HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FOSRENOL safely and effectively. See full prescribin

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2011-04-29 14:25:21
37DEPARTMENT OF HEALTH & HUMAN SERVICES  Public Health Service Food and Drug Administration Silver Spring, MD 20993

DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993

Add to Reading List

Source URL: www.fda.gov

Language: English
38la bonne A.P charte OK vatoquinol

la bonne A.P charte OK vatoquinol

Add to Reading List

Source URL: www.petnvetss.com

Language: English - Date: 2012-09-19 17:30:57
39LANTHANUM CARBONATE (FOSRENOL®) AND SEVELAMER HCL (RENAGEL®) APPLICATION Please make sure this form is co-signed before faxing to the pharmacy (with prescription). Health Authority:  Name:

LANTHANUM CARBONATE (FOSRENOL®) AND SEVELAMER HCL (RENAGEL®) APPLICATION Please make sure this form is co-signed before faxing to the pharmacy (with prescription). Health Authority: Name:

Add to Reading List

Source URL: www.bcrenalagency.ca

Language: English - Date: 2012-08-08 13:56:24
40

PDF Document

Add to Reading List

Source URL: www.nature.com

Language: English - Date: 2011-03-31 06:48:39